205 related articles for article (PubMed ID: 21814031)
1. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Takahashi S
Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
[TBL] [Abstract][Full Text] [Related]
2. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Takahashi S
Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
5. [Cancer treatment-induced bone loss. Treatment for breast cancer].
Yamada K; Kohno N
Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Lønning PE
J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
[No Abstract] [Full Text] [Related]
7. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
8. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
9. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
10. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
[TBL] [Abstract][Full Text] [Related]
11. Management of bone loss due to endocrine therapy during cancer treatment.
Khan MI
Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
[TBL] [Abstract][Full Text] [Related]
12. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
[TBL] [Abstract][Full Text] [Related]
14. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive therapies in oncology and their effects on cancer progression.
Bundred N
Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
[TBL] [Abstract][Full Text] [Related]
16. Bone complications of androgen deprivation therapy: screening, prevention, and treatment.
Lattouf JB; Saad F
Curr Opin Urol; 2010 May; 20(3):247-52. PubMed ID: 20224416
[TBL] [Abstract][Full Text] [Related]
17. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: an update.
Bogado CE; Boailchuk JA; Zanchetta MB; Massari FE; Zanchetta JR
Drugs Today (Barc); 2011 Aug; 47(8):605-13. PubMed ID: 21850283
[TBL] [Abstract][Full Text] [Related]
20. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
